Publication Date:
1996-03-22
Description:
One reason for the poor immunogenicity of many tumors may be that they cannot provide signals for CD28-mediated costimulation necessary to fully activate T cells. It has recently become apparent that CTLA-4, a second counterreceptor for the B7 family of costimulatory molecules, is a negative regulator of T cell activation. Here, in vivo administration of antibodies to CTLA-4 resulted in the rejection of tumors, including preestablished tumors. Furthermore, this rejection resulted in immunity to a secondary exposure to tumor cells. These results suggest that blockade of the inhibitory effects of CTLA-4 can allow for, and potentiate, effective immune responses against tumor cells.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Leach, D R -- Krummel, M F -- Allison, J P -- CA09179/CA/NCI NIH HHS/ -- CA40041/CA/NCI NIH HHS/ -- CA57986/CA/NCI NIH HHS/ -- New York, N.Y. -- Science. 1996 Mar 22;271(5256):1734-6.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Cancer Research Laboratory, University of California, Berkeley, CA 94720, USA.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/8596936" target="_blank"〉PubMed〈/a〉
Keywords:
Abatacept
;
Animals
;
Antibodies/immunology
;
Antigens, CD
;
Antigens, CD28/immunology
;
Antigens, CD80/immunology
;
Antigens, Differentiation/*immunology
;
CTLA-4 Antigen
;
Female
;
Graft Rejection
;
*Immunoconjugates
;
Immunologic Memory
;
*Lymphocyte Activation
;
Mice
;
Mice, Inbred A
;
Mice, Inbred BALB C
;
Neoplasm Transplantation
;
Neoplasms, Experimental/*immunology
;
T-Lymphocytes/*immunology
;
Transfection
;
Tumor Cells, Cultured
Print ISSN:
0036-8075
Electronic ISSN:
1095-9203
Topics:
Biology
,
Chemistry and Pharmacology
,
Computer Science
,
Medicine
,
Natural Sciences in General
,
Physics
